Lipopolysaccharide desensitizes monocytes–macrophages to CD40 ligand stimulation

Anna Sinistro,1 Chiara Ciaprina,1 Silvia Natoli,2 Emanuele Sussarello,2 Francesca Calò Carducci,1 Cristiana Almerighi,3 Marcella Capozzi,1 Francesca Bolacchi,4 Giovanni Rocchi1 and Alberto Bergamini1,4
1Department of Public Health and Cellular Biology, Chair of Infectious Diseases, 2Intensive Care Unit, 3Department of Internal Medicine, Chair of Gastroenterology, and 4Diagnostic imaging-Molecular Imaging-Radiotherapy and Interventional radiology, University of Rome ‘Tor Vergata’, Rome, Italy

doi:10.1111/j.1365-2567.2007.02648.x
Received 8 August 2006; revised 7 December 2006, 8 January 2007, 16 April 2007; accepted 25 April 2007.
Correspondence: Dr A. Bergamini, Dipartimento di Sanità Pubblica e Biologia Cellulare, Cattedra di Malattie Infettive, Università di Roma ‘Tor Vergata’, Via Montpellier 1, 00173 Roma, Italy. Email: bergamini@med.uniroma2.it
Senior author: Dr A. Bergamini

Summary

Polymicrobial sepsis induces the suppression of macrophage function as determined by a reduction of pro-inflammatory cytokine production upon re-exposure to lipopolysaccharide (LPS) in vitro. Here, we examined whether macrophages were refractory to only LPS or if they were unable to respond to other stimuli such as CD40 ligand (CD40L). Monocytic cells exposed in vitro to LPS showed a dose-dependent reduction of their ability to produce interleukin-12 and tumour necrosis factor-α upon subsequent CD40L stimulation, as compared to cells stimulated with CD40L alone. Similarly, LPS interfered with the up-regulation of CD40, CD80 and CD86 induced by CD40L in monocytic cells. The effect of LPS on the response of monocytes to CD40L was similar whether these cells were directly exposed to LPS or cocultured with LPS-pretreated cells, indicating that soluble factors released by LPS stimulation could mediate tolerance to CD40L. We also show that the functional alterations induced by LPS in monocytes can be reversed by indomethacin, thus suggesting a role for inducible cyclooxygenase in mediating the LPS-induced hyporesponsive state of monocytes to CD40L. In conclusion, we propose that in vitro CD40L tolerance may be an appropriate model of monocyte alteration observed during septic immunosuppression and may help in the development of novel therapeutic strategies.

Keywords: CD40 ligand; lipopolysaccharide; macrophages; sepsis

Introduction

During the late stages of sepsis, massive deterioration of the immune response occurs, which is characterized by suppression of both macrophage and lymphocyte immune function. Indeed, a significant percentage of survivors of sepsis have an elevated risk of succumbing to bacterial superinfection.1

CD40 is a molecule with molecular weight 50 000 that is expressed on different cell types including monocyte–macrophages.2 The human form of a ligand for CD40 (CD40L) is a type II integral membrane protein expressed primarily on activated CD4+ T cells.3,4 Upon CD40 engagement, monocytic cells secrete a vast array of cytokines, among them, interleukin-12 (IL-12) and tumour necrosis factor-α (TNF-α), which are important in promoting and maintaining T helper type 1 (Th1) and pro-inflammatory responses during bacterial infection.3–7 Activation of macrophages by CD40L also results in the up-regulation of surface molecules, such as CD40, CD80 and CD86, which play a critical role in T-cell activation.3–5 Thus, CD40–CD40L interaction is an essential step in triggering the adaptive immune response6,7 and is very likely to play a prominent role during sepsis, as demonstrated by the increased mortality observed in septic animals with mutations of the CD40L gene.8,9

Lipopolysaccharide (LPS), a major cell wall component of Gram-negative bacterial organisms, can alone instigate many of the pathophysiological events that occur within the host during a septic episode.10,11 Endotoxin tolerance was first described as the temporary insensitivity of a host to a repeated LPS challenge with respect to systemic inflammation parameters. This phenomenon is associated with functional alterations to the monocytes and can be imitated in vitro. After pretreatment with an initial activating LPS dose, a second LPS stimulation of monocytic cells causes reduced production of pro-inflammatory
cytokines, when compared with non-LPS-pretreated controls.

In contrast to previous studies, which defined the functional state of monocyctic cells during endotoxin tolerance only in terms of LPS desensitization, we intended to characterize LPS-tolerized monocytes in terms of their capacity to respond to CD40L stimulation. Here we show the altered production of IL-12 and TNF-α, and the reduced expression of molecules that are important for T-cell stimulation by human monocytes stimulated by CD40L after an initial exposure to LPS. Furthermore, we tested the role of endogenous mediators produced during the initial LPS exposure in the alterations expressed by the monocytes.

**Materials and methods**

**Cells**

Peripheral blood obtained from healthy donors was enriched for peripheral blood mononuclear cells by centrifugation over Ficoll–Hypaque. These peripheral blood mononuclear cells were then further enriched for monocytes by elutriation as previously described. Cells obtained by this method are >90% monocytes as determined by fluorescence-activated cell sorting (FACS) analysis. The cells were cultured in RPMI-1640 medium supplemented with 20% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, referred to as complete medium. The cells were kept at 37°C in a humidified atmosphere of 5% CO2 in air, in 96-well V-bottom plates (Corning Incorporated, Corning, NY) at a concentration of 5 x 10^5 cells/well/250 μl.

**Compounds**

Immunex (Seattle, WA) provided soluble trimeric recombinant CD40L. *Escherichia coli* 0111/B4 LPS and indomethacin were purchased from Sigma Chemical Co. (St Louis, MO). Recombinant granulocyte–macrophage colony-stimulating factor (GM-CSF) was obtained from Sanofi Research Institute (East Hanover, NJ) and contained 5–4 x 10^6 chronic myelogenous leukaemia units per milligram of glycoprotein. Interleukin-4 was obtained from Genzyme (Cambridge, MA).

**Limulus amoebocyte lysate test**

All the compounds and media used in this study were analysed for endotoxin contamination by the *Limulus* amoebocyte lysate test (QCL-1000, BioWhittaker, Inc, Walkersville, MD). All the samples analysed were found to be free of endotoxin contamination (less than 0·1 EU/ml).

**Materials and methods**

**Cells**

Peripheral blood obtained from healthy donors was enriched for peripheral blood mononuclear cells by centrifugation over Ficoll–Hypaque. These peripheral blood mononuclear cells were then further enriched for monocytes by elutriation as previously described. Cells obtained by this method are >90% monocytes as determined by fluorescence-activated cell sorting (FACS) analysis. The cells were cultured in RPMI-1640 medium supplemented with 20% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, referred to as complete medium. The cells were kept at 37°C in a humidified atmosphere of 5% CO2 in air, in 96-well V-bottom plates (Corning Incorporated, Corning, NY) at a concentration of 5 x 10^5 cells/well/250 μl.

**Compounds**

Immunex (Seattle, WA) provided soluble trimeric recombinant CD40L. *Escherichia coli* 0111/B4 LPS and indomethacin were purchased from Sigma Chemical Co. (St Louis, MO). Recombinant granulocyte–macrophage colony-stimulating factor (GM-CSF) was obtained from Sanofi Research Institute (East Hanover, NJ) and contained 5–4 x 10^6 chronic myelogenous leukaemia units per milligram of glycoprotein. Interleukin-4 was obtained from Genzyme (Cambridge, MA).

**Limulus amoebocyte lysate test**

All the compounds and media used in this study were analysed for endotoxin contamination by the *Limulus* amoebocyte lysate test (QCL-1000, BioWhittaker, Inc, Walkersville, MD). All the samples analysed were found to be free of endotoxin contamination (less than 0·1 EU/ml).

**Materials and methods**

**Cells**

Peripheral blood obtained from healthy donors was enriched for peripheral blood mononuclear cells by centrifugation over Ficoll–Hypaque. These peripheral blood mononuclear cells were then further enriched for monocytes by elutriation as previously described. Cells obtained by this method are >90% monocytes as determined by fluorescence-activated cell sorting (FACS) analysis. The cells were cultured in RPMI-1640 medium supplemented with 20% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, referred to as complete medium. The cells were kept at 37°C in a humidified atmosphere of 5% CO2 in air, in 96-well V-bottom plates (Corning Incorporated, Corning, NY) at a concentration of 5 x 10^5 cells/well/250 μl.

**Compounds**

Immunex (Seattle, WA) provided soluble trimeric recombinant CD40L. *Escherichia coli* 0111/B4 LPS and indomethacin were purchased from Sigma Chemical Co. (St Louis, MO). Recombinant granulocyte–macrophage colony-stimulating factor (GM-CSF) was obtained from Sanofi Research Institute (East Hanover, NJ) and contained 5–4 x 10^6 chronic myelogenous leukaemia units per milligram of glycoprotein. Interleukin-4 was obtained from Genzyme (Cambridge, MA).

**Limulus amoebocyte lysate test**

All the compounds and media used in this study were analysed for endotoxin contamination by the *Limulus* amoebocyte lysate test (QCL-1000, BioWhittaker, Inc, Walkersville, MD). All the samples analysed were found to be free of endotoxin contamination (less than 0·1 EU/ml).

**Materials and methods**

**Cells**

Peripheral blood obtained from healthy donors was enriched for peripheral blood mononuclear cells by centrifugation over Ficoll–Hypaque. These peripheral blood mononuclear cells were then further enriched for monocytes by elutriation as previously described. Cells obtained by this method are >90% monocytes as determined by fluorescence-activated cell sorting (FACS) analysis. The cells were cultured in RPMI-1640 medium supplemented with 20% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, referred to as complete medium. The cells were kept at 37°C in a humidified atmosphere of 5% CO2 in air, in 96-well V-bottom plates (Corning Incorporated, Corning, NY) at a concentration of 5 x 10^5 cells/well/250 μl.

**Compounds**

Immunex (Seattle, WA) provided soluble trimeric recombinant CD40L. *Escherichia coli* 0111/B4 LPS and indomethacin were purchased from Sigma Chemical Co. (StLouis, MO). Recombinant granulocyte–macrophage colony-stimulating factor (GM-CSF) was obtained from Sanofi Research Institute (East Hanover, NJ) and contained 5–4 x 10^6 chronic myelogenous leukaemia units per milligram of glycoprotein. Interleukin-4 was obtained from Genzyme (Cambridge, MA).

**Limulus amoebocyte lysate test**

All the compounds and media used in this study were analysed for endotoxin contamination by the *Limulus* amoebocyte lysate test (QCL-1000, BioWhittaker, Inc, Walkersville, MD). All the samples analysed were found to be free of endotoxin contamination (less than 0·1 EU/ml).

**Materials and methods**

**Cells**

Peripheral blood obtained from healthy donors was enriched for peripheral blood mononuclear cells by centrifugation over Ficoll–Hypaque. These peripheral blood mononuclear cells were then further enriched for monocytes by elutriation as previously described. Cells obtained by this method are >90% monocytes as determined by fluorescence-activated cell sorting (FACS) analysis. The cells were cultured in RPMI-1640 medium supplemented with 20% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, referred to as complete medium. The cells were kept at 37°C in a humidified atmosphere of 5% CO2 in air, in 96-well V-bottom plates (Corning Incorporated, Corning, NY) at a concentration of 5 x 10^5 cells/well/250 μl.

**Compounds**

Immunex (Seattle, WA) provided soluble trimeric recombinant CD40L. *Escherichia coli* 0111/B4 LPS and indomethacin were purchased from Sigma Chemical Co. (St Louis, MO). Recombinant granulocyte–macrophage colony-stimulating factor (GM-CSF) was obtained from Sanofi Research Institute (East Hanover, NJ) and contained 5–4 x 10^6 chronic myelogenous leukaemia units per milligram of glycoprotein. Interleukin-4 was obtained from Genzyme (Cambridge, MA).

**Limulus amoebocyte lysate test**

All the compounds and media used in this study were analysed for endotoxin contamination by the *Limulus* amoebocyte lysate test (QCL-1000, BioWhittaker, Inc, Walkersville, MD). All the samples analysed were found to be free of endotoxin contamination (less than 0·1 EU/ml).
Coculture experiments were performed as follows. Fresh elutriated monocyte–macrophages (10⁶) were plated in the bottom of a 24-well plate and were cocultured, separated by a microporous membrane (0.45 μm in diameter; Falcon 3095, Becton Dickinson, Mountain View, CA, USA), with monocyte–macrophages from the same donor, pre-exposed for 45 min to different concentrations of LPS (mock pre-exposed cells were used as control). Just before plating, LPS-treated cells were extensively washed to remove excess LPS. After 24 hr of culture, LPS-treated cells were discarded and non-LPS-treated cells were collected, washed and stimulated with 500 ng/ml CD40L. Thirty minutes after CD40L stimulation, 1 μg/ml brefeldin A was added. Sixteen hours after brefeldin A addition the cells were analysed by FACS for intracellular cytokine production. As shown by Brossart et al., 13 7 days exposure to CD40L induces maximal expression of CD40, CD80 and CD86 on monocytes. Thus, to evaluate the effect of LPS on the ability of CD40L to modulate the expression of CD40, CD80 and CD86, monocyte–macrophages were cultured after LPS challenge or cocultured with LPS-exposed cells as described above, for 7 days in the presence of 500 ng/ml CD40L. At the end of the incubation period the non-LPS-treated cells were analysed by FACS for CD40, CD80 and CD86 expression.

**Surface marker and intracellular cytokine staining**

After incubation, the cells were washed and stained for surface markers by incubation with the appropriate surface marker for 30 min in the dark on ice. Cells were then washed twice and either analysed by FACS to determine cell surface antigen expression or resuspended in Cytofix/Cytoperm solution (PharMingen) for 20 min in the dark on ice. The permeabilized cells were washed twice and stained for intracellular cytokines in the dark on ice for 30 min. After intracellular cytokine staining, the cells were washed and resuspended in 200 μl phosphate-buffered saline with 0.4% paraformaldehyde for FACS analysis.

**FACS analysis**

Flow cytometry was performed using a FACScan flow cytometer and analysed with CellQuest software (Becton Dickinson). For each analysis, 10⁶ events were gated on CD14 expression and a light scatter gate was designed to include only viable cells. Isotype-matched negative controls antibodies (PharMingen) were used to verify the staining specificity.

**Assessment of cell viability**

The number of live cells was determined by trypan blue dye assay. In all the experiments performed the number of non-viable cells was consistently <3%.

**Statistics**

All numerical data were expressed as means ± standard errors of the means. P-values were derived from a two-tailed Student t-test. A P-value ≤ 0.05 was considered significant.

**Results**

**LPS induces tolerance to CD40L stimulation**

First, we confirmed the capacity of LPS to induce endotoxin tolerance in monocytes. As depicted in Fig. 1, monocytes exposed to LPS showed a decreased ability to produce IL-12 and TNF-α in response to subsequent LPS exposure. This suppression was significant with LPS concentrations of 10 ng/ml, whereas pretreatment with LPS at concentrations of 100–1000 ng/ml induced maximum suppression.

Further experiments were carried out to determine whether LPS could also induce tolerance to CD40L stimulation. As shown in Fig. 2(a), monocytic cells pre-exposed to LPS showed a dose-dependent reduction of their...
LPS reduces the response of monocytic cells to CD40L

Figure 2. Effect of LPS pretreatment on CD40L-induced intracellular cytokine production. (a) Monocytes were treated with graded doses of LPS or medium for 24 hr, washed, and then stimulated with 500 ng/ml CD40L. (b) Monocytes were cocultured, separated by a microporous membrane, with cells from the same donor pre-exposed to LPS or medium for 45 min, and then washed. After 24 hr of coculture the cells were stimulated with 500 ng/ml CD40L. Intracellular cytokine production was assessed by FACS. Less than 1% IL-12 and TNF-α production was found in mock-CD40L stimulated control samples (data not shown). The data represent the means of three experiments carried out with cells from three different donors. The error bars represent the standard errors. The asterisk indicates P < 0.05. The cytokine intensities of fluorescence (mean ratio ± SD, arbitrary units), respectively, for TNF-α and IL-12 were as follows. (a) monocytes mock-pretreated with LPS, 18.45 ± 7.3 and 13.6 ± 2.9; monocytes pretreated with 1 ng/ml LPS, 8.4 ± 2.5 and 5.6 ± 1.8; monocytes pretreated with 10 ng/ml LPS, <5 and <5; monocytes pretreated with 100 ng/ml LPS, <5 and <5; monocytes pretreated with 1000 ng/ml LPS, <5 and <5; and (b) monocytes mock-pretreated with LPS, 21.5 ± 8 and 15.3 ± 3.2; monocytes pretreated with 1 ng/ml LPS, 10.67 ± 3.7 and 6.9 ± 1.5; monocytes pretreated with 10 ng/ml LPS, 5.1 ± 1.1 and <5; monocytes pretreated with 100 ng/ml LPS, <5 and <5; monocytes pretreated with 1000 ng/ml LPS, <5 and <5.

ability to produce IL-12 and TNF-α upon subsequent CD40L stimulation compared to cells stimulated with CD40L alone. Significant suppression of IL-12 and TNF-α was observed in cells pretreated with LPS at concentrations as low as 1 ng/ml. More than 90% suppression of IL-12 and TNF-α was found in monocytes pre-exposed to 100–1000 ng/ml LPS.

We then asked whether soluble factors released by LPS stimulation could mediate tolerance to CD40L. In these experiments, before CD40L stimulation, monocytes were cocultured separated by a microporous membrane, with cells from the same donor exposed or not to LPS. As shown in Fig. 2(b), the indirect effect of LPS on the cytokine response of monocytes to CD40L strictly paralleled that observed in cells directly pretreated by LPS, with more than 50% and 90% reduction of IL-12 and TNF-α production obtained by 1 ng/ml LPS and 100–1000 ng/ml LPS, respectively. These data were confirmed and expanded by testing cytokine release in supernatants. As shown in Fig. 3, in monocytes cocultured with LPS-pretreated cells the secretion of both IL-12 and TNF-α was significantly reduced by pretreatment with 1 ng/ml LPS, and almost completely suppressed by 1000 ng/ml LPS.

LPS prevents expression of costimulatory surface molecules induced by CD40L

As shown in Fig. 4, LPS was able to interfere with the up-regulation of CD40, CD80 and CD86 induced by CD40L in monocyctic cells. Again, the effect of LPS on the response of monocytes to CD40L was similar whether these cells were directly exposed to LPS (Fig. 4a) or cocultured with LPS-pretreated cells (Fig. 4b). In particular,
a significant reduction of CD40, CD80 and CD86 expression was observed in LPS-treated cultures with LPS concentrations ≤ 100 ng/ml, as compared to cells stimulated with CD40L alone. Both GM-CSF and IL-4 are currently used to generate dendritic cells from blood monocytes. Differentiation of monocytes into dendritic cells results in the up-regulation of (along with many other molecules) CD40, CD80 and CD86. To evaluate whether the interference of LPS in CD40L-triggered activation of surface marker expression was specific or not, further experiments were carried out in which modulation of CD40, CD80 and CD86 was induced by GM-CSF/IL-4 in the presence or not of LPS. Figure 5 shows that LPS failed to affect the up-modulation of CD40, CD80 and CD86 induced by GM-CSF/IL-4.

**Discussion**

We have characterized LPS-tolerized monocytes in terms of their capacity to respond to CD40L stimulation. Our findings demonstrate that tolerance in such cells involves a distinct functional state of activation and/or differentiation, which is not restricted to LPS tachyphylaxis. Indeed, pretreatment with LPS substantially reduced the response of monocytic cells to CD40L in terms of both cytokine production and expression of costimulatory molecules. We also show that these functional alterations induced by LPS in monocytes can be reverted by indomethacin, suggesting a role for inducible COX in mediating the LPS-induced hyporesponsive state of monocytes to CD40L.
IL-12 is an immunoregulatory cytokine that is critical to the orchestration of cell-mediated immune responses in both the innate and adaptive immune systems. IL-12 augments the production of interferon-γ and other cytokines from natural killer cells and T cells. Furthermore, IL-12 appears to be a vital component of the host defence against both Gram-positive and Gram-negative bacteria, as shown by the heightened host resistance conferred by IL-12 administration in several models of bacterial infection. IL-12 is produced largely by monocyte–macrophages and dendritic cells upon LPS or CD40L triggering. Therefore, the likely relevance of endotoxin
A. Sinistro et al.

![Figure 9. Forward- and side-scatter profiles and CD14+ gating of the cells. (a) Monocytes were selected on the basis of their forward- and side-scatter profiles. (b, c) The side scatter gain was then appropriately lowered and the threshold for forward- and side-scatter was increased to exclude lymphocytes, dead cells and cellular debris and the cells that stained positive for CD14 (as compared with the CD3-stained control) were gated to analyse cytokine or surface markers expression.](image)

A number of different cell types perform APC functions, including macrophages. However, macrophages that express low-level costimulatory molecules constitutively are not competent APC and require activation by CD40L first to up-regulate costimulatory activity and to become competent APC. Here, we found that LPS prevents the CD40L-mediated up-regulation of CD80 and CD86. In addition, LPS significantly affected the ability of CD40L to up-modulate the expression of CD40, which can further reduce the responsiveness of monocyte–macrophages to CD40L. With respect to experimental sepsis, recent studies indicate that the macrophage antigen-presenting capacity appears to become dysfunctional by 24 hr after induction of sepsis and remains at subnormal levels for up to 14 days after. More interestingly, Sugimoto et al. reported an inverse relationship between CD40 expression and susceptibility to infections and outcome in bacteremic patients. However, other authors have reported that CD86 expression is decreased on peritoneal macrophages after sepsis, while CD80 and CD40 expression is unaltered. Differences between our in vitro results and in vivo studies may be in part the result of the presence, in vivo, of additional mediators able to affect co-receptor expression. Alternatively, it should be noted that in our experimental system the effect on co-receptor expression was observed at LPS concentrations equal or higher than 100 ng/ml. Such amounts of circulating LPS are not usually detected during sepsis, even though they can be found in the microenvironment at the site of infection.

It has been recently demonstrated that the decreased TNF-α production capacity of monocytes observed during endotoxin tolerance is mediated by IL-10 and TGF-β produced during the primary LPS stimulation. However, we found that neutralization of endogenous IL-10 and TGF-β failed to prevent the LPS-induced reduced monocyte susceptibility to CD40L, suggesting that other factors are involved as the cause of this phenomenon. LPS is a potent trigger of prostaglandin E2 (PGE2) in monocytes. The interaction of PGE2 with the PGE2 receptor on monocyte–macrophages results in reduced activation of the Janus family protein tyrosine kinase JAK3. Recent findings indicate that CD40 engagement in human monocytes induces JAK3 phosphorylation and subsequent activation of transcription factors, suggesting a critical role of JAK3 as signal transducer after CD40L stimulation. Indeed, in CD40-triggered monocytes, the inhibition of JAK3 with the specific inhibitor WHI-P-154 drastically prevented cytokine production and the expression of maturation markers. Therefore, it is conceivable that CD40L-response suppression by LPS is mediated by PGE2. This hypothesis is consistent with the ability of indomethacin to ameliorate the ability of LPS-exposed mononuclear cells to respond to CD40L stimulation. In vivo and in vitro experiments indicate that the induction of...
inducible COX by endotoxins results in elevated production of PGE$_2$ that is linked to the immunological abnormalities seen during sepsis.$^{44-47}$ Several studies of the effects of non-selective COX inhibition during sepsis have been conducted with the intent of determining whether COX inhibition is beneficial and safe. Available data indicate that COX inhibitors are generally safe and may ameliorate several clinical and immunological parameters.$^{46,48-50}$ However, treatment with COX inhibitors did not appear to improve the rate of survival in patients with sepsis even though it has been shown to ameliorate the extent of IL-12 reduction and to provide survival advantage in septic animals.$^{45,51,52}$

Lipopolysaccharide-containing endotoxins are potent activators of the innate immune system. As such, endotoxins are central to the pathogenesis of Gram-negative sepsis.$^{18,53-55}$ Massive LPS-induced release of pro-inflammatory cytokines in vivo has been associated with the induction of acute septic shock. In this context, it is worth stressing the role of CD40 engagement in contributing to the host early inflammatory response to bacterial infection.$^{16,17}$ However, death as a result of hyperactivation of the innate immune system is an uncommon result of exposure to endotoxins. Moreover, immunomodulatory therapy directed at inhibition of the inflammatory response has been largely unsuccessful.$^{29,56}$ Indeed, it has been observed that subsequent to septic shock there often follows a clinical state characterized by profound immunosuppression. Modern medicine is now able potentially to control acute hyperinflammatory situations, but there is no established therapy to deal with the high risk associated with immunosuppression. We propose that in vitro CD40L tolerance may be an appropriate model of monocyte alteration observed during septic immunosuppression and may help in the development of novel therapeutic strategies.

References

23. Zhang X, Morrison DC. Lipopolysaccharide-induced selective priming effects on tumor necrosis factor α and nitric oxide...


